These businesses are at the top of their respective industries, but you wouldn't know it by looking at their stock prices.
The market doesn't always get a growth stock's valuation right, and when it's wrong, there's often an opportunity to make a hearty dollop of dosh -- and it's always good to feel as if you're a step ahead of the market. On that note, two growth stocks look favorably priced right now, and there's good reason to think they'll keep growing in the years ahead. Israeli medical aesthetics company InMode (NASDAQ: INMD) is a stellar investment opportunity thanks to its slightly cheap shares and its finely tuned growth engine.
Wall Street analysts are expecting that 23andMe's (NASDAQ: ME) stock will hit around $5.69 within a year, which means they think it can grow to more than double its current price of $2.61. In 2019, it reported sales of $156.3 million, which means that its compound annual growth rate (CAGR) from 2019 through 2024 would be 31.3%.